Kardigan, Inc. is a clinical-stage precision therapeutics company. It is developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Its pipeline of products includes Danicamtiv, Ataciguat and Tonlamarsen. Danicamtiv is an investigational oral cardiac atrial and ventricular myosin activator for the treatment of genetic dilated cardiomyopathy caused by pathogenic variants in myosin heavy chain 7 (MYH7) and titin, the common sarcomeric gene variants. Ataciguat is an investigational oral, once-daily soluble guanylate cyclase activator aimed at slowing the progression of calcific aortic valve stenosis in patients with moderate diseases. Tonlamarsen is an investigational liver-directed antisense oligonucleotide administered once-monthly via subcutaneous injection, targeting hepatic angiotensinogen for the management of blood pressure in acute severe hypertension post-hospitalization. Prolaio is a clinical intelligence platform.
종목 코드 KARD
회사 이름Kardigan Inc
상장일Jun 18, 2026
CEOGianakakos (Tassos Anastasios)
직원 수420
유형Ordinary Share
회계 연도 종료Jun 18
주소506 Carnegie Center Drive, Suite 201
도시PRINCETON JUNCTION
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호08540
전화14155733220
웹사이트http://www.kardigan.bio
종목 코드 KARD
상장일Jun 18, 2026
CEOGianakakos (Tassos Anastasios)